B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
AGEN
AgenusFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The best post-print bull read is that Q1 moved BOT+BAL from setup toward execution: early-access revenue reached $4.6 million, BATTMAN enrollment started in April, and the Zydus deal added capital plus manufacturing support, while the SEC investigation ended with no enforcement recommendation [#8-K-2026-05-11] [#10-Q-2026-05-11].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Clinical and regulatory execution risk remains high because the thesis still depends on BATTMAN enrollment, data-package completion, and planned U.S./E.U. submission pathways [#8-K-2026-05-11] [#10-Q-2026-05-11].
Momentum
99
Value
52
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.00 · Bull $6.00 · Bear $1.50Analysis 2026-05-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $19.50
Why
Momentum99 · Δ7d +1.3
Value52 · Δ7d -0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Clinical and regulatory execution risk remains high because the thesis still depends on BATTMAN enrollment, data-package completion, and planned U.S./E.U. submission pathways [#8-K-2026-05-11] [#10-Q-2026-05-11].
- • Debt maturities remain meaningful, with $5.1 million due in June 2026 and $24.75 million due in November 2026, increasing refinancing and dilution risk [#10-Q-2026-05-11].
- • The bear read remains stronger in the near term because the company still carries going-concern language, needs additional capital to reach profitability, has near-dated debt maturities, and is relying on collections, financing, and trial execution to keep the plan intact.
Catalyst clock
2026-05-31
ASCO 2026 melanoma Phase 2 presentation
Lead driver: Value · See fundamentals
Momentum
99
9% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
-0.3
Value
52
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+11.3
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 98.8 / Value 52.4 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-14. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$321.9M
Beta
1.62
Shares Out
45.02M
P/E (TTM) · Derived
-2102.9
P/S (TTM)
1.03
P/FCF (TTM) · Derived
-2.74
Rev YoY
+34.4%
EPS YoY
-98.5%
Gross Margin
+96.0%
Op Margin
+27.0%
Net Debt
$331.9M
Current Ratio
0.34
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data